Sema4 reports third quarter 2022 financial results and new strategic direction

Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from centrellis®

SMFR Ratings Summary

SMFR Quant Ranking